《Chinese Journal of Rehabilitation Theory and Practice》 ›› 2022, Vol. 28 ›› Issue (7): 803-808.doi: 10.3969/j.issn.1006-9771.2022.07.010

Previous Articles     Next Articles

Susceptibility gene polymorphisms of primary knee osteoarthritis: a systematic review

LUO Shengfei1,HU Zhibo2,WANG Ninghua3,MIN Hongwei4,5,ZHANG Dejian4,LIU Kemin4,5()   

  1. 1. The Second Hospital of Tianjin Medical University, Tianjin 300211, China
    2. Tianjin Medical University, Tianjin 300134, China
    3. The First Hospital of Peking University, Beijing 100034, China
    4. China Rehabilitation Research Center, Beijing Bo'ai Hospital, Beijing 100068, China
    5. Capital Medical University School of Rehabilitation Medicine, Beijing 100068, China
  • Received:2021-11-12 Revised:2022-02-14 Published:2022-07-25 Online:2022-08-08
  • Contact: LIU Kemin E-mail:keminlqliu@sina.com
  • Supported by:
    Foundamental Research Funds for General Public Welfare Research Institute(2019CZ-12)

Abstract:

Objective To conduct a systematic review of the susceptibility gene polymorphism sites of primary knee osteoarthritis (PKO).

Methods The literature on genetic susceptibility and gene polymorphisms of PKO were retrieved from PubMed, Web of Science, CNKI, Wanfang Data, and China Biomedical Literature Database from establishment of the library to December, 2020, and systematically reviewed.

Results A total of 42 papers on the polymorphism sites of human PKO susceptibility genes were included, involving cellular signaling pathways related to PKO pathogenesis, including inflammatory response, receptor signaling pathway, transcription factor signaling pathway, bone-related signaling pathway, etc. Multiple gene polymorphism sites located in inflammatory factor genes, chemokine genes, Toll-like receptor genes, transcription factor genes, obesity-related genes, and bone-related genes.

Conclusion Inflammatory factor genes and bone-associated allele polymorphisms are likely to be related to PKO susceptibility.

Key words: primary knee osteoarthritis, genetic susceptibility, single nucleotide polymorphism, therapeutic targets, systematic review

CLC Number: